The stock of Wave Life Sciences Ltd (NASDAQ:WVE) hit a new 52-week high and has $43.11 target or 9.00% above today’s $39.55 share price. The 8 months bullish chart indicates low risk for the $961.83 million company. The 1-year high was reported on Nov, 25 by Barchart.com. If the $43.11 price target is reached, the company will be worth $86.56M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock increased 1.67% or $0.65 during the last trading session, hitting $39.55. About 39,187 shares traded hands. Wave Life Sciences Ltd (NASDAQ:WVE) has risen 187.72% since April 22, 2016 and is uptrending. It has outperformed by 182.31% the S&P500.
Analysts await Wave Life Sciences Ltd (NASDAQ:WVE) to report earnings on March, 29. They expect $-0.69 EPS, down 46.81% or $0.22 from last year’s $-0.47 per share. After $-0.75 actual EPS reported by Wave Life Sciences Ltd for the previous quarter, Wall Street now forecasts -8.00% EPS growth.
Wave Life Sciences Ltd (NASDAQ:WVE) Ratings Coverage
Out of 5 analysts covering WAVE Life Sciences (NASDAQ:WVE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. WAVE Life Sciences has been the topic of 5 analyst reports since December 7, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Monday, December 7 by Leerink Swann. As per Monday, December 7, the company rating was initiated by JMP Securities. As per Monday, December 7, the company rating was initiated by Suntrust Robinson. The stock of Wave Life Sciences Ltd (NASDAQ:WVE) has “Buy” rating given on Monday, December 7 by SunTrust. Jefferies initiated Wave Life Sciences Ltd (NASDAQ:WVE) on Monday, December 7 with “Buy” rating.
According to Zacks Investment Research, “WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington’s disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington’s disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore.”
More notable recent Wave Life Sciences Ltd (NASDAQ:WVE) news were published by: Marketwatch.com which released: “WAVE Life Sciences Ltd.” on October 14, 2015, also Businesswire.com with their article: “WAVE Life Sciences Enters Collaboration with Pfizer to Develop Genetically …” published on May 05, 2016, Businesswire.com published: “WAVE Life Sciences to Advance Next-Generation Nucleic Acid Therapies to …” on May 09, 2016. More interesting news about Wave Life Sciences Ltd (NASDAQ:WVE) were released by: Businesswire.com and their article: “WAVE Life Sciences to Present at the Jefferies 2016 London Healthcare Conference” published on November 07, 2016 as well as Businesswire.com‘s news article titled: “WAVE Life Sciences Announces Plan to Deliver Six Clinical Programs by 2018” with publication date: January 29, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.